NASDAQ: SLNO: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Soleno Therapeutics, Inc.

Core Viewpoint - A securities fraud class action lawsuit has been filed against Soleno Therapeutics, Inc. for allegedly making materially false and misleading statements regarding its Phase 3 clinical trial program for its product DCCR, which is intended for treating hyperphagia in individuals with Prader-Willi syndrome [1][4][5]. Company Overview - Soleno Therapeutics, Inc. is a pharmaceutical company based in Redwood City, California, focused on developing therapies for rare diseases. Its only commercial product is diazoxide choline extended-release tablets (DCCR) [3]. Lawsuit Details - The lawsuit was filed on behalf of investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025, and alleges that the company failed to disclose significant safety concerns related to DCCR, which could affect its commercial viability [1][5]. - Key allegations include misrepresentation of safety concerns in the Phase 3 clinical trial, leading to greater risks than disclosed, and potential adverse events post-launch, which could impact patient adoption and regulatory standing [4][7]. Financial Impact - Following the release of financial results on November 4, 2025, Soleno's stock price dropped over 26% due to concerns raised by a report from Scorpion Capital regarding the clinical trial program and its implications for DCCR's market performance [7]. Investor Actions - Investors affected by the alleged fraud are encouraged to contact Kessler Topaz Meltzer & Check, LLP for potential recovery options, with a deadline to seek lead plaintiff status set for May 5, 2026 [2][5][9].